Abstract:Real world study(RWS) refers to the process of collecting real world data related to the health of research subjects in the real world environment for pre-set clinical problems and obtaining the status of drug use and potential benefits/risks through analysis. The data are derived from the hospital information system(HIS), medical insurance system, disease registration system, adverse drug reaction monitoring system, etc. Human use experience of traditional Chinese medicine(TCM) is a new concept put forward by experts after summarizing the problems existing in clinical trials of new TCM drugs. The data come partially from the real world, and more importantly, such key elements as the formulated prescriptions of new TCM drugs, principles and methods, and clinical applications should be covered. RWS is mainly used for adverse drug reaction monitoring after marketing, benefit evaluation of listed drugs, decision-making of medical treatment and medical insurance, as well as supervision and approval of special medical devices and special drugs. It is complementary to randomized controlled clinical trials. Human use experience is suitable for the research and development of Chinese medicinal compound preparations and the expansion of functions and indications. There are no special provisions for clinical indications and target population. There exists a sequential relationship between the human use experience and clinical trials. Specifi-cally, the summarization of human use experience provides good support for the design and implementation of clinical trials, which is an important segment in the research and development of new TCM drugs. The correlation between real-world data and research results and their reliability should be ensured in RWS, and the unreality should be avoided. The key to summarizing the human use experience is to identify the clinical orientation, target population, course of treatment, usage and dosage of new TCM drugs, and it should be noted that human use experience does not only mean clinical experience. Experimental clinical trial(PCT), a type of study in the real world, has been commonly employed for the summary of human use experience. RWS and human use experience are different research designs targeting different clinical questions in the research and development of new TCM drugs, which can be flexibly selected depending on the actual situation.

Real World Study and Pharmacoeconomic Evaluation

The use of real-world data for clinical investigation of effectiveness in drug development

Pharmacoeconomic Analysis in New Drug Development: A Pragmatic Approach to Efficiency Studies

Drug Review and Approval Policies Based on Real-world Evidence in China and the United States: A Comparative Study

Clinical Pharmacology Applications of Real‐World Data and Real‐World Evidence in Drug Development and Approval–An Industry Perspective

Real-world Evidence versus Randomized Controlled Trial: Clinical Research Based on Electronic Medical Records

Observational studies to emulate randomized trials: Some real‐world barriers

Estimands in Real-World Evidence Studies

Pharmacoepidemiology: Using randomised control trials and observational studies in clinical decision‐making

Conducting Real-world Evidence Studies on the Clinical Outcomes of Diabetes Treatments

Application of Path Analysis in Pharmacoeconomics

Application of Health Insurance Data in Pharmacoeconomics Evaluation--International Experience and Related Advices

On the use of RWD in support of regulatory submission in drug development

Methodological Considerations when Analysing and Interpreting Real-World Data.

Real-World Evidence: A Primer

Decentralized Clinical Trials in the Era of Real-World Evidence: A Statistical Perspective

Contemporary Practice and Considerations for Real-World Data Source Identification and Feasibility Assessment

[Application of real world study and human use experience in research and development of new traditional Chinese medicine drugs].

Acceptability of using Real-World Data to Estimate Relative Treatment Effects in Health Technology Assessments: Barriers and Future Steps

[Expert consensus on pharmacoeconomic evaluations alongside clinical trials (2024 edition)]

A Practical Analysis Procedure on Generalizing Comparative Effectiveness in the Randomized Clinical Trial to the Real-world Trialeligible Population